(PARIS2024) FRANCE-PARIS-OLY-HANDBALL

(PARIS2024) FRANCE-PARIS-OLY-HANDBALL

(240731) -- PARIS, July 31, 2024 Photo by Xinhua/ABACAPRESS.COM) -- Ivan Martinovic (R) of Croatia vies with Julian Koester of Germany during the handball men's preliminary round Group A match between Croatia and Germany at Paris 2024 Olympic Games in Paris, France, July 31, 2024. Photo by Xinhua/ABACAPRESS.COM/Li Jing)

  • Product Code
  • ILEA003074443
  • Registered date
  • 2024/7/31 00:00:00
  • Credit
  • Abaca Press / Kyodo News Images
  • Media source
  • Xinhua/ABACA
  • Media size
  • 5000 × 3570 pixel
  • Resolution
  • 200 dpi
  • Deployment size
  • 2.80(MB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Sanofi Group To Sell Doliprane To US Fund

    Sanofi Group To Sell Doliprane To US Fund

    Illustration of Doliprane in Paris, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Florian Poitout/ABACAPRESS.COM
      Sanofi Group To Sell Doliprane To US Fund

      Sanofi Group To Sell Doliprane To US Fund

      Illustration of Doliprane in Paris, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Florian Poitout/ABACAPRESS.COM
        Sanofi Group To Sell Doliprane To US Fund

        Sanofi Group To Sell Doliprane To US Fund

        Illustration of Doliprane in Paris, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Florian Poitout/ABACAPRESS.COM
          Sanofi Group To Sell Doliprane To US Fund

          Sanofi Group To Sell Doliprane To US Fund

          Illustration of Doliprane in Paris, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Florian Poitout/ABACAPRESS.COM
            Sanofi Group To Sell Doliprane To US Fund

            Sanofi Group To Sell Doliprane To US Fund

            Illustration of Doliprane in Paris, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Florian Poitout/ABACAPRESS.COM
              Sanofi Group To Sell Doliprane To US Fund

              Sanofi Group To Sell Doliprane To US Fund

              Illustration of Doliprane in Paris, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Florian Poitout/ABACAPRESS.COM
                Sanofi Group To Sell Doliprane To US Fund

                Sanofi Group To Sell Doliprane To US Fund

                Illustration of Doliprane in Paris, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Florian Poitout/ABACAPRESS.COM
                  Sanofi Group To Sell Doliprane To US Fund

                  Sanofi Group To Sell Doliprane To US Fund

                  Illustration of Doliprane in Paris, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Florian Poitout/ABACAPRESS.COM
                    Sanofi Group To Sell Doliprane To US Fund

                    Sanofi Group To Sell Doliprane To US Fund

                    Illustration of Doliprane in Paris, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Florian Poitout/ABACAPRESS.COM
                      Sanofi Group To Sell Doliprane To US Fund

                      Sanofi Group To Sell Doliprane To US Fund

                      Illustration of Doliprane in Paris, France on October 11, 2024. Sanofi's Doliprane to become American with CD&R's takeover of Opella. The French pharmaceutical group has confirmed that it is in exclusive negotiations with CD&R. The American fund is seeking to acquire its Opella subsidiary, which produces Doliprane. Photo by Florian Poitout/ABACAPRESS.COM